INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
November 05, 2018 19:02 ET
|
Schall Law
LOS ANGELES, Nov. 05, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cocrystal Pharma, Inc....
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
October 08, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre to conduct Phase 2a study evaluating CC-31244 for the treatment of hepatitis C - Asia market represents one of the largest hepatitis C virus carrier...
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
September 20, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
August 09, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
June 28, 2018 07:35 ET
|
Cocrystal Pharma, Inc.
- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal”...
Cocrystal Pharma Announces Inclusion in Russell Microcap® Index
June 25, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony
June 04, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, June 04, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
May 11, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, May 11, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Cocrystal Pharma to Present at the Fred Hutch and Merck Infectious Disease Summit
May 10, 2018 08:30 ET
|
Cocrystal Pharma, Inc.
- Presentation on Thursday, May 10 at 11:15 AM PDT - ATLANTA, GA and BOTHELL, WA, May 10, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical...
Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus
April 03, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
– Company on track to commence patient enrollment and dosing in Q2 2018 – – Topline data from Phase 2a study expected in Q4 2018 – ATLANTA, GA and BOTHELL, WA, April 03,...